3rd Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
—
Expenses
$6,790,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements Korea Free Trade Agreement: intellectual property, market access and public health International market access and intellectual property issues Trade enforcement issues

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
JAMES BRYANT HALL —
TOM MOORE —
BYRON PATTERSON —
BILLY TAUZIN —

Contacted: SENATE; Commerce, Dept of (DOC); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; White House Office; Natl Economic Council (NEC); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO)

Bills named: H.R. 3012 (111th)

Copyright/Patent/Trademark CPT

H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements S. 369, Preserve Access to Affordable Generics Act: patent settlements S. 515, Patent Reform Act of 2009: reforms of the patent laws S. 610, Patent Reform Act of 2009: reforms of the patent laws S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics International intellectual property issues

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER Spec. Asst. to Pres. for Leg. Affrs.-White Hse.;, Asst. Comm'r for Leg.-FDA; Spec. Asst. for, Oversight-HHS; Spec. Asst. to Sec.-HHS; Spec., Asst. Offc. of Asst. Sec. for Leg.-HHS; Spec., Asst. Offc. of White Hse. Liaison-DOD; Conf., Asst. Offc. of Sec.-DOL
ROBERT FILIPPONE —
JAMES BRYANT HALL —
MIMI KNEUER —
DAVID KORN —
KENDRA MARTELLO —
TOM MOORE —
BRIAN NAGLE —
BYRON PATTERSON —
ANNE PRITCHETT Sen. Policy Analyst-White House Drug Policy, Offc., Exec. Offc. of Pres.
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
BILLY TAUZIN —
JENNIFER VAN METER —
MICHAEL PAUL WOODY —

Contacted: State, Dept of (DOS); Congressional Budget Office (CBO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); Natl Economic Council (NEC); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); White House Office

Bills named: H.R. 1706 (111th), S. 369 (111th), S. 726 (111th), S. 515 (111th), H.R. 1260 (111th), S. 610 (111th), H.R. 1548 (111th), H.R. 1427 (111th)

Health Issues HCR

H.R. 444, 340B Program Improvement and Integrity Act: 340B program issues (drug pricing program for covered entities) H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics H.R. 1859, Independent Drug Education and Outreach Act of 2009: academic detailing H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness H.R. 3200, Americas Affordable Health Choices Act: regulatory approval pathway for follow-on biologics, 340B program issues, comparative effectiveness S. 422, The Heart Disease Education, Analysis Research, and Treatment (HEART) for Women Act: new drug application requirements S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics S. 767, Independent Drug Education and Outreach Act of 2009: academic detailing S. 914, Cures Acceleration Network and National Institutes of Health Reauthorization of 2009: basic research and development S. 1142, Informed Health Care Decision Making Act: drug labeling S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation S. 1679, Affordable Health Choices Act: health reform, regulatory approval pathway for follow on biologics, 340B program issues Americas Healthy Future Act of 2009 Chairmans Mark Senate Finance Committee: comparative effectiveness

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER Spec. Asst. to Pres. for Leg. Affrs.-White Hse.;, Asst. Comm'r for Leg.-FDA; Spec. Asst. for, Oversight-HHS; Spec. Asst. to Sec.-HHS; Spec., Asst. Offc. of Asst. Sec. for Leg.-HHS; Spec., Asst. Offc. of White Hse. Liaison-DOD; Conf., Asst. Offc. of Sec.-DOL
JENNIFER MIRANDA BRYANT —
RANDY BURKHOLDER —
ANDREA JEAN DOUGLAS —
DANIEL DURHAM Act. Dep. Asst. Sec. Health Pol., Dep. to Dep., Asst. Sec. Health Pol., Sen. Advr. Health Pol.-, HHS; Act. Assoc. Comm'r. & Dep. Assoc., Comm'r. Ret. Policy-SSA; Policy Analyst &, Budget Exam.-OMB
ROBERT FILIPPONE —
LEA FISHER Leg. Asst.-Rep. Bob Etheridge
GREGORY GIERER LA, LC-Sen. Christopher Dodd; Staff Asst.-, Rep. Rosa DeLauro
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
ANN KAPLAN —
MIMI KNEUER —
HALLIE AMANDA MARANCHICK —
KENDRA MARTELLO —
TOM MOORE —
BRIAN NAGLE —
BYRON PATTERSON —
ANNE PRITCHETT Sen. Policy Analyst-White Hse. Drug Policy, Offc., Exec. Offc. of the Pres.
LORI REILLY —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON Staff Asst., LC, LA, Dep. LD-Sen. Pat Roberts
BILLY TAUZIN —
STEVE TILTON —
JENNIFER VAN METER —
MICHAEL PAUL WOODY —

Contacted: State, Dept of (DOS); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); Patent & Trademark Office (PTO); Medicare Payment Advisory Commission (MedPAC); Agency for Healthcare Research & Quality (AHRQ); Office of Management & Budget (OMB); Food & Drug Administration (FDA); SENATE; Natl Economic Council (NEC); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); White House Office; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: S. 1213 (111th), S. 914 (111th), S. 1142 (111th), H.R. 444 (111th), S. 422 (111th), H.R. 3200 (111th), S. 1679 (111th), H.R. 2502 (111th), S. 525 (111th), H.R. 1548 (111th), H.R. 1427 (111th), H.R. 2824 (111th), S. 1232 (111th), H.R. 1298 (111th), S. 767 (111th), S. 488 (111th), S. 726 (111th), H.R. 1859 (111th)

Medicare/Medicaid MMM

H.R. 684, Medicare Prescription Drug Savings and Choice Act: Part D issues H.R. 3200, Americas Affordable Health Choices Act: Medicaid rebate issues, Part D issues, health reform issues S. 301, Physician Payments Sunshine Act of 2009: transparency issues S. 330, Medicare Prescription Drug Savings and Choice Act: Part D issues S. 1110, Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009: Medicare payment issues S. 1380, Medicare Payment Advisory Commission Reform Act of 2009: Medicare payment issues Americas Healthy Future Act of 2009 Chairmans Mark Senate Finance Committee: Medicaid rebate issues, Part D issues, health reform issues Senate Finance Committee options papers

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER Spec. Asst. to Pres. for Leg. Affrs.-White Hse.;, Asst. Comm'r for Leg.-FDA; Spec. Asst. for, Oversight-HHS; Spec. Asst. to Sec.-HHS; Spec., Asst. Offc. of Asst. Sec. for Leg.-HHS; Spec., Asst. Offc. of White Hse. Liaison-DOD; Conf., Asst. Offc. of Sec.-DOL
JENNIFER MIRANDA BRYANT —
RANDY BURKHOLDER —
ANDREA JEAN DOUGLAS —
DANIEL DURHAM Act. Dep. Asst. Sec. Health Pol., Dep. to Dep., Asst. Sec. Health Pol., Sen. Advr. Health Pol.-, HHS; Act. Assoc. Comm'r. & Dep. Assoc., Comm'r. Ret. Policy-SSA; Policy Analyst &, Budget Exam.-OMB
ROBERT FILIPPONE —
LEA FISHER Leg. Asst.-Rep. Bob Etheridge
GREGORY GIERER LA, LC-Sen. Christopher Dodd; Staff Asst.-, Rep. Rosa DeLauro
JAMES BRYANT HALL —
ANN KAPLAN —
MIMI KNEUER —
HALLIE AMANDA MARANCHICK —
TOM MOORE —
BRIAN NAGLE —
BYRON PATTERSON —
LORI REILLY —
RICHARD SMITH —
HEATHER STRAWN —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON Staff Asst., LC, LA, Dep. LD-Sen. Pat Roberts
BILLY TAUZIN —
STEVE TILTON —
JENNIFER VAN METER —
MICHAEL PAUL WOODY —

Contacted: U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); SENATE; White House Office; Office of Management & Budget (OMB); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); Natl Economic Council (NEC); Office of Natl Drug Control Policy (NDCP); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); State, Dept of (DOS)

Bills named: S. 301 (111th), H.R. 684 (111th), H.R. 3200 (111th), S. 330 (111th), S. 1110 (111th), S. 1380 (111th)

Budget/Appropriations BUD

H.R. 2847, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2010: trade infringement H.R. 2892, Department of Homeland Security Appropriations Act, 2010: importation H.R. 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding H.R. 3293, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2010, and for other purposes: comparative effectiveness, NIH funding, pandemic funding S. 1298, Department of Homeland Security Appropriations Act, 2010: importation S. 1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
DAVID BOYER Spec. Asst. to Pres. for Leg. Affrs.-White Hse.;, Asst. Comm'r for Leg.-FDA; Spec. Asst. for, Oversight-HHS; Spec. Asst. to Sec.-HHS; Spec., Asst. Offc. of Asst. Sec. for Leg.-HHS; Spec., Asst. Offc. of White Hse. Liaison-DOD; Conf., Asst. Offc. of Sec.-DOL
LEA FISHER Leg. Asst.-Rep. Bob Etheridge
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
MIMI KNEUER —
KENDRA MARTELLO —
TOM MOORE —
BRIAN NAGLE —
BYRON PATTERSON —
LORI REILLY —
MATTHEW L SULKALA —
JENNIFER ANNE SWENSON Staff Asst., LC, LA, Dep. LD-Sen. Pat Roberts
BILLY TAUZIN —
STEVE TILTON —

Contacted: Patent & Trademark Office (PTO); White House Office; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Congressional Budget Office (CBO); Office of Natl Drug Control Policy (NDCP); Natl Economic Council (NEC); U.S. Trade Representative (USTR); State, Dept of (DOS); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Medicare Payment Advisory Commission (MedPAC); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: S. 1298 (111th), S. 1406 (111th), H.R. 2892 (111th), H.R. 3293 (111th), H.R. 2847 (111th), H.R. 2997 (111th)

Environment/Superfund ENV

H.R. 1145, National Water Research and Development Initiative Act of 2009: water quality issues H.R. 1191, Safe Drug Disposal Act of 2009: drug take back H.R. 1359, Secure and Responsible Drug Disposal Act of 2009: drug take back H.R. 3202, Water Protection and Reinvestment Act of 2009: water quality issues S. 1005, Water Infrastructure Financing Act: water quality issues

LobbyistCovered position, as disclosed
LEA FISHER Leg. Assist.-Rep. Bob Etheridge
JAMES BRYANT HALL —
VALERIE HARDIN JEWETT —
KENDRA MARTELLO —
BRIAN NAGLE —
MATTHEW L SULKALA —

Contacted: Medicare Payment Advisory Commission (MedPAC); State, Dept of (DOS); Office of Management & Budget (OMB); White House Office; Office of Natl Drug Control Policy (NDCP); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Commerce, Dept of (DOC); Agency for Healthcare Research & Quality (AHRQ); U.S. Trade Representative (USTR)

Bills named: H.R. 1359 (111th), S. 1005 (111th), H.R. 1145 (111th), H.R. 3202 (111th), H.R. 1191 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.